We're aware of the resistance to amitraz. We're not necessarily proactively talking to the company. We pretty much have all the active ingredients registered elsewhere in the world right now. There is some biotech development. Some companies are developing new types of products that they are doing research on to see if they would work, and when they come talk to us, we obviously consider the current situation. Obviously, everything needs to pass the risk assessment.
On May 31st, 2023. See this statement in context.